🚀 Gate Square Creator Certification Incentive Program Is Live!
Join Gate Square and share over $10,000 in monthly creator rewards!
Whether you’re an active Gate Square creator or an established voice on another platform, consistent quality content can earn you token rewards, exclusive Gate merch, and massive traffic exposure!
✅ Eligibility:
You can apply if you meet any of the following:
1️⃣ Verified creator on another platform
2️⃣ At least 1,000 followers on a single platform (no combined total)
3️⃣ Gate Square certified creator meeting follower and engagement criteria
Click to apply now 👉
Zuo Li Pharmaceutical: The development work of Ling Yi Bio's Parkinson's pipeline LY-N001 is ongoing.
Jin10 data reported on September 7th that Zoli Pharmaceutical stated during an institutional survey that the research and development of Lingyi Bio's Parkinson's pipeline LY-N001 is continuing to advance, with the main preclinical research work already completed. This pipeline targets Parkinson's subtype patients associated with GBA1 gene mutations, with future goals of filing IND applications in China and the US and conducting clinical research as well as global market layout. Lingyi Bio is a company focused on the R&D of innovative drugs for single-gene genetic diseases, positioned to develop gene therapies with differentiated advantages. The company increased its investment in Lingyi Bio by 20 million yuan in April 2025.